Trostberg

EQS-News: Alzchem Group AG: EBITDA increase of 32.4 % to EUR 81.4 million – continuing on the road to success

Retrieved on: 
Wednesday, March 13, 2024

Despite a persistently challenging environment, the company succeeded in significantly increasing all key earnings figures and at EUR 540.6 million (2022: EUR 542.2 million) maintaining Group sales almost at the previous year’s record level.

Key Points: 
  • Despite a persistently challenging environment, the company succeeded in significantly increasing all key earnings figures and at EUR 540.6 million (2022: EUR 542.2 million) maintaining Group sales almost at the previous year’s record level.
  • Primarily due to the increasing weight of the higher-margin growth segment Specialty Chemicals, Alzchem succeeded in significantly increasing Group EBITDA by 32.4% to EUR 81.4 million in the fiscal year 2023 (previous year: EUR 61.4 million).
  • Operating cash flow also developed strongly in the fiscal year 2023, which was once again clearly positive at EUR 72.7 million (2022: EUR -4.2 million).
  • Thanks to them, the Alzchem Group remains on course for success,” explains Andreas Lösler, CFO of Alzchem Group AG.

EQS-News: Alzchem Group AG reports positive business development in the first half of 2023

Retrieved on: 
Thursday, August 3, 2023

At EUR 277.0 million, Group sales improved by 3% compared to the prior-year period, in which EUR 269.8 million was generated.

Key Points: 
  • At EUR 277.0 million, Group sales improved by 3% compared to the prior-year period, in which EUR 269.8 million was generated.
  • For this reason, a further expansion is currently being implemented so that additional capacities will be available as early as the fourth quarter of 2023.
  • In line with the positive Group sales development, earnings before interest, taxes, depreciation and amortization (EBITDA) also increased in the first half of 2023.
  • Andreas Niedermaier, CEO of Alzchem Group AG: “The market challenges remain enormous and the economic environment is also very fragile.

EQS-News: Alzchem Group AG ensures continuity on the Management Board: Contract extension with CEO Andreas Niedermaier until 2026

Retrieved on: 
Friday, May 12, 2023

Alzchem Group AG ensures continuity on the Management Board: Contract extension with CEO Andreas Niedermaier until 2026

Key Points: 
  • Alzchem Group AG ensures continuity on the Management Board: Contract extension with CEO Andreas Niedermaier until 2026
    The issuer is solely responsible for the content of this announcement.
  • Alzchem Group AG ensures continuity on the Management Board: Contract extension with CEO Andreas Niedermaier until 2026
    Trostberg, 12 Mai 2023 – The Supervisory Board of Alzchem Group AG has extended early the service contract of Chief Executive Officer Andreas Niedermaier, which runs until 31 December 2023, by 3 years until 2026.
  • Andreas Niedermaier has been with Alzchem Group AG since 1999 and has been a member of the Management Board since 2011.
  • Markus Zöllner, Chairman of the Supervisory Board of Alzchem Group AG: “With the extension of Andreas Niedermaier’s contract, we are ensuring stability and continuity for the Alzchem Group.

EQS-News: Alzchem Group AG achieves significant sales and earnings growth in the first quarter of 2023

Retrieved on: 
Thursday, May 4, 2023

Trostberg, May 4, 2023 – Alzchem Group AG, a vertically integrated specialty chemicals supplier with a leading market position in selected niche markets, significantly increased its sales in the first quarter of 2023 compared to the same period of the previous year.

Key Points: 
  • Trostberg, May 4, 2023 – Alzchem Group AG, a vertically integrated specialty chemicals supplier with a leading market position in selected niche markets, significantly increased its sales in the first quarter of 2023 compared to the same period of the previous year.
  • This segment achieved a 31% increase in sales, or EUR 20.5 million, to EUR 85.8 million, thus setting another record.
  • EBITDA recorded growth of 11% to EUR 18.9 million in the first quarter of 2023.
  • For the fiscal year 2023, Alzchem Group anticipates a continuation of its solid growth course.

EQS-News: Alzchem Group AG: Alzchem Group AG achieves highest sales in the company’s history in the fiscal year 2022 with EUR 542.2 million (+28.4%)

Retrieved on: 
Tuesday, February 28, 2023

Among the biggest challenges were the outbreak of the Ukraine war and the resulting price jumps for energy, raw materials and in logistics.

Key Points: 
  • Among the biggest challenges were the outbreak of the Ukraine war and the resulting price jumps for energy, raw materials and in logistics.
  • Nevertheless, the Alzchem Group was able to achieve record sales of EUR 542.2 million, an increase of 28.4% compared to the previous year.
  • Consolidated annual result for the fiscal year 2022 increased by 8.9% from EUR 27.8 million to EUR 30.2 million.
  • Slightly rising sales (up to EUR 590 million) and a slight increase in EBITDA (up to EUR 70 million) are forecast.

EQS-News: Alzchem Group AG with strong sales growth of 31.4% in the 9-month period 2022

Retrieved on: 
Friday, October 28, 2022

Trostberg, October 26, 2022 Alzchem Group AG, a vertically integrated specialty chemicals supplier with a leading market position in selected niche markets, achieved dynamic growth in the 9-month period of 2022, generating sales of EUR 409.0 million.

Key Points: 
  • Trostberg, October 26, 2022 Alzchem Group AG, a vertically integrated specialty chemicals supplier with a leading market position in selected niche markets, achieved dynamic growth in the 9-month period of 2022, generating sales of EUR 409.0 million.
  • This corresponds to an increase of 31.4% compared to the prior-year period, in which sales of EUR 311.2 million were recorded.
  • Alzchem generated Group sales of around EUR 422.3 million and EBITDA of around EUR 62.0 million in 2021.
  • 26.10.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.

DGAP-News: Alzchem Group AG increases sales by 25.3% in the first half of 2022

Retrieved on: 
Tuesday, July 26, 2022

By contrast, sales in the pharmaceuticals, agrochemicals and basic chemicals businesses (NITRALZ) and agricultural fertilizers (Perlka) were down on the previous year.

Key Points: 
  • By contrast, sales in the pharmaceuticals, agrochemicals and basic chemicals businesses (NITRALZ) and agricultural fertilizers (Perlka) were down on the previous year.
  • The successful passing on of substantial cost increases to a large extent via corresponding price increases is also reflected in the earnings development of the Alzchem Group in the first half of 2022.
  • Andreas Niedermaier, CEO of Alzchem Group AG: The environment did not make it easy for us in the first half of 2022.
  • The broad product range of Alzchem Group AG includes dietary supplements, precursors for corona tests and pharmaceutical raw materials.

DGAP-News: Annual General Meeting 2022 of Alzchem Group AG: Broad shareholder approval for growth course and dividend increase

Retrieved on: 
Thursday, May 5, 2022

Annual General Meeting 2022 of Alzchem Group AG: Broad shareholder approval for growth course and dividend increase

Key Points: 
  • Annual General Meeting 2022 of Alzchem Group AG: Broad shareholder approval for growth course and dividend increase
    The issuer is solely responsible for the content of this announcement.
  • Annual General Meeting 2022 of Alzchem Group AG: Broad shareholder approval for growth course and dividend increase
    Trostberg, 5 May 2022 Todays virtual Annual General Meeting of Alzchem Group AG expressed its continued confidence in the Management Board and the Supervisory Board by discharging them for the fiscal year 2021 and approved all agenda items with a large majority.
  • We are grateful for the broad approval of the Annual General Meeting, as it once again represents a great vote of confidence in our work and strategy.
  • At the same time, we also see it as a great incentive for the further successful development of Alzchem Group AG.

DGAP-News: Alzchem Group AG achieves record sales of EUR 129.4 million (+24%) in the first quarter of 2022

Retrieved on: 
Thursday, April 28, 2022

The Specialty Chemicals segment recorded a 15% increase in sales in the first three months of 2022, with plant capacity utilization remaining high.

Key Points: 
  • The Specialty Chemicals segment recorded a 15% increase in sales in the first three months of 2022, with plant capacity utilization remaining high.
  • Specifically, Alzchem generated EBITDA of EUR 17.1 million in the first quarter of 2022, up 2% on the previous year's figure of EUR 16.7 million.
  • For the fiscal year 2022, Alzchem now forecasts "strongly to particularly strongly increasing" consolidated sales of up to EUR 520 million (previously: up to EUR 480 million).
  • In 2021, Alzchem generated consolidated sales of around EUR 422.3 million and EBITDA of around EUR 62.0 million.

DGAP-News: Alzchem Group AG receives award from EcoVadis for its sustainability successes

Retrieved on: 
Thursday, April 21, 2022

With 70 out of 100 possible points, Alzchem is among the top 4% of companies worldwide assessed by EcoVadis in the field of basic chemical manufacturing.

Key Points: 
  • With 70 out of 100 possible points, Alzchem is among the top 4% of companies worldwide assessed by EcoVadis in the field of basic chemical manufacturing.
  • Among the various ESG topics, Alzchem achieved the highest score for environment and the greatest improvement over 2020 for sustainable procurement.
  • Dr. Georg Weichselbaumer, CSO of Alzchem Group AG: "We are proud to have been awarded the Gold Medal again by EcoVadis.
  • The broad product range of Alzchem Group AG includes dietary supplements, precursors for corona tests and pharmaceutical raw materials.